Bryn Mawr Capital Management’s Fortress Biotech FBIO Stock Holding History

Bryn Mawr Capital Management’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,753	Closed	-$78K	–	93
2018 Q2	$78K	Buy	1,753 +556	+46%	+$31.3K	0.07%	92
2018 Q1	$82K	Buy	1,197 +214	+22%	+$13.5K	0.07%	84
2017 Q4	$65K	Hold	983	–	–	0.09%	67
2017 Q3	$65K	Buy	983 +35	+4%	+$2.36K	0.07%	79
2017 Q2	$68K	Buy	+948	New	+$56K	0.08%	71

Other funds holding FBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

STRS Ohio Columbus, Ohio $25.2B AUM 30.31% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Bryn Mawr Capital Management's FBIO Position: Q3 2018 in Review

Bryn Mawr Capital Management sold out of Fortress Biotech (FBIO) in Q3 2018, closing a stake of 1,753 shares — an estimated $78K sold.

Bryn Mawr Capital Management first reported a position in FBIO in Q2 2017 and held it in 5 quarters. The position peaked at $82K in Q1 2018. 65 funds tracked by Wall St. Rank hold FBIO as of Q3 2018.

Bryn Mawr Capital Management reported no remaining Fortress Biotech position as of Q3 2018 after selling out during the quarter.
Bryn Mawr Capital Management sold 1,753 Fortress Biotech shares in Q3 2018, an estimated $78K.
Bryn Mawr Capital Management first reported a position in Fortress Biotech in Q2 2017 and held it in 5 quarters.
Bryn Mawr Capital Management's Fortress Biotech position peaked at $82K in Q1 2018.
65 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2018.

Based on Bryn Mawr Capital Management's 13F filing for Q3 2018, filed 7 Nov 2018.